Article
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
British journal of cancer - 5 Feb 2013
Boeck S, Jung A, Laubender R P, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens M R, Gauler T C, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten T F, Mansmann U, Kirchner T, Heinemann V
Abstract excerpt
BACKGROUND: We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the anti-EGFR agent erlotinib within the phase 3 randomised AIO-PK0104 study. METHODS: AIO-PK0104 was a multicenter trial comparing gemcitabine/erlotinib followed by capecitabine with capecitabine/erlotinib followed by gemcitabine in advanced PC; primary study end...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.